LRLeonardo Costa Ribeiro

Leonardo Costa Ribeiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leonardo Costa Ribeiro has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Capitalist Dynamics and Endogenous Innovation: A Complex-Systems Model with Multifractal Properties

    by Leonardo Costa Ribeiro, Pedro Mendes Loureiro, Leonardo Gomes de Deus, Eduardo da Motta e Albuquerque

    This article advances on efforts to model capitalism as a complex system through a dialogue between Marx’s, Schumpeterian, and evolutionary insights. Its main modeling contribution is to endogenize the creation of new technologies, a crucial feature of capitalist dynamics. The starting point of our modeling exercise is Marx’s elaboration on the interaction between the tendencies and the countertendencies for the rate of profit to fall, proposing that falls in the rate of profit trigger innovations that reconfigure capitalism. This is done in three steps. After reviewing theoretical mechanisms that indicate a connection between falling profitability and innovation, we revisit previous debates on long waves and the history of US capitalism to investigate the role of crises in systemic shifts. We then develop a formal model, test its main results against empirical properties of the US profit rate, and analyze simulation results. One crucial finding is the discovery of multifractal properties, indicating that capitalism has different but articulated levels of self-organization across its scales. JEL Classification: P160, O33, B510

  • Emergence of a global innovation system: an inter-temporal analysis through a network of networks

    by Leonardo Costa Ribeiro, Jorge Nogueira De Paiva Britto, Eduardo Da Motta E Albuquerque

    This paper investigates the intertemporal behaviour of a network of networks that represents an emerging global system of innovation. The research question in this investigation is whether this net...

  • Open Access

    National innovation systems represented as a moving and expanding universe

    by Leonardo Costa Ribeiro, Américo Tristão Bernardes, Eduardo da Motta e Albuquerque

    This paper proposes a representation of national innovation systems (NSIs) as a moving and interacting universe of points in a three-dimensional space. This universe moves and expands, following the technological leadership of the most advanced NSIs. This expansion is not homogeneous, leading to different groups that when analyzed uncovers the center-periphery divide – a moving frontier. Each NSI is a point in a three-dimensional universe, condensing three data: GDP per capita, scientific articles per capita, patents per capita. Looking at NSIs populating a universe offers a point of view that brings new elements our interpretation, therefore this paper is organized to investigate the changes in this expanding universe: its population, how to measure its expansion, the clustering of NSIs, frontiers between groups, trajectories of selected countries.

  • Open Access

    The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities

    by André Soares Motta-Santos, Kenya Valéria Micaela de Souza Noronha, Leonardo Costa Ribeiro, Jeffrey Gow, Khorshed Alam, Mônica Viegas Andrade

    Objective This study examines the monoclonal antibody innovation landscape through patent activity and market data. Methods A dedicated dataset was constructed by linking multiple sources (Antibody Society, Orange Book, Ark Patent Intelligence, US Patent and Trademark Office, PATSTAT, Purple Book, US Veterans Affairs, US-FDA, and ORBIS), covering patents registered between 1986 and 2019. Data analysis comprised six components: (i) a general description of the dataset, (ii) an examination of monoclonal antibody patents and approval trends, (iii) an analysis of therapeutic indications, (iv) a characterization of patent holders and producers through descriptive and network analyses, (v) an assessment of shareholder influence, including common-ownership patterns, and (vi) an evaluation of monoclonal antibody prices. Results The dataset included 63 monoclonal antibodies, 1732 unique patents, 89 active pharmaceutical ingredients, 34 producers, and 214 therapeutic indications, of which 36.5% were single indication, while the average number of secondary indications was 3.78. Roche, Johnson & Johnson, Eli Lilly, Amgen, and Novartis led reference medicine production, while Amgen and Pfizer were notable in biosimilars, with only five companies producing both. Shareholders such as BlackRock, UBS, Vanguard, and JPMorgan exerted strong market influence in monoclonal antibody production. Prices were extremely high, averaging US$127,430 per course or year (s = US$142,509), with 42.1% of monoclonal antibodies priced above US$100,000. Conclusions While monoclonal antibodies have transformed modern medicine and improved safety and effectiveness, their persistently high prices, reinforced by market concentration and financial investor influence, raise serious concerns for equity and social welfare.


  • The pharmaceutical market: a transdisciplinary description of concepts and their implications

    by André Soares Motta-Santos, Kenya Valéria Micaela de Souza Noronha, Leonardo Costa Ribeiro, Jeffrey Gow, Khorshed Alam, Mônica Viegas Andrade

    The pharmaceutical industry has delivered innovative therapies that substantially improved health outcomes. However, concerns persist regarding high drug prices and delays in the entry of competitors. This article provides a comprehensive and transdisciplinary overview of the pharmaceutical market. References were identified and selected from Medline, Lilacs, Embase, and Google Scholar until thematic saturation. Particular attention is devoted to the market for monoclonal antibodies (mAbs), given their high prices and expanding commercial relevance. The industry is heavily dependent on innovation, with firms investing significant resources in risky R&D and charging high prices for new technologies. Although companies justify elevated prices based on R&D expenditures, additional market dynamics also sustain high pricing. Operating under imperfect competition, pharmaceutical products often exhibit characteristics of merit and credence goods, while practices such as evergreening and reverse payments reinforce market power. Patients' willingness to pay, especially for life-saving treatments, remains high despite limited understanding of expected outcomes due to informational asymmetry. Drug prices reflect the interaction of market structure, R&D investment, licensing arrangements, and patient behavior. Biopharmaceuticals entail added complexity and cost. Monopolistic or oligopolistic conditions can result in suboptimal pricing and unmet demand, highlighting the need for stronger regulatory oversight.


  • Evidence of creative clusters in Portugal

    by Ana Flávia Machado, Cínthia Santos Silva, Leonardo Costa Ribeiro, Pedro Costa


  • Open Access

    Mapping the platform economy: a methodology for identifying and locating digital platform companies using NLP techniques

    by Leonardo Costa Ribeiro, Victo Silva, Tulio Chiarini

    Identifying digital platform companies has proven to be a formidable task due to the intricate nature of these organizations. This complexity often results in incomplete depictions, exacerbated by the inherent tendency of digital platforms to blur traditional sectoral boundaries. To bridge this knowledge gap, we propose an innovative methodology that harnesses the power of Natural Language Processing (NLP) techniques for the systematic identification of digital platform companies on a global scale. Moreover, we present an applied exercise aimed at creating a comprehensive world map that precisely locates these platform companies. Our approach and exercise offer four distinct contributions: (i) our methodology validates an artificial intelligence algorithm-based approach for identifying companies based on the products and services they offer. This not only enhances the accuracy of our identification process but also sets a precedent for the application of AI in this context; (ii) by facilitating the identification of digital platform firms, our methodology empowers researchers in the fields of business and economics. This empowerment enables a more precise and comprehensive understanding of the intricacies of the platform economy, thereby facilitating in-depth research and analysis; (iii) our findings provide invaluable insights for policymakers who grapple with the complexities of the platform economy. These insights serve as a crucial tool for crafting effective regulations and fostering healthy competition within the digital marketplace, ultimately benefiting consumers and businesses alike; (iv) through the visual representation of platform company distribution on our map, we offer a tangible means to test and refine existing theories regarding how these companies operate and thrive in various regions. This empirical validation contributes to the advancement of platform geography theories, particularly those related to value creation and appropriation.


  • Open Access

    Understanding Brazil's Platform Economy: Trends and Regulatory Challenges

    by Victo José da Silva Neto, Tulio Chiarini, Leonardo Costa Ribeiro

    The proliferation of digital platforms has transformed economic landscapes, orchestrating connections among diverse agents and fostering innovation. Yet, the regulatory oversight remains a concern, prompting the need for comprehensive data on the platform economy. This is the first study that provides aggregate data on Brazil's digital platform economy. Our research aimed to address two critical issues: Are Brazilian companies aligned with the global platformization trend, and what distinctive attributes characterize them? Identifying 556 platform companies in the country, the study confirms Brazil's active participation in the global platform economy. However, these companies, primarily young and SMEs, exhibit regional concentration and reliance on foreign investments. The study outlines the need for nuanced regulatory frameworks considering company size, market share, and user base. In conclusion, the research sheds light on Brazil's participation in the global platform economy, emphasizing its unique attributes and offering insights crucial for policymakers and future investigations.